VolitionRX Ltd

Insider sales at VolitionRX reveal routine liquidity moves, not fear, as the company’s high‑purity liquid‑biopsy platform pushes toward FDA clearance and partnership wins.

VolitionRX insider sales, negative P/E, and its epigenetic cancer‑detection tech show a speculative biotech story—watch regulatory moves and payer deals for potential upside.

VolitionRX insider buying signals confidence amid volatility—investors weigh RSU grants, exec purchases, and epigenetic cancer strategy for future upside.

Insider buying at VolitionRx signals management confidence after a strong Phase II trial. Discover how Rootsaert’s $0.28 purchase could foreshadow FDA filings, new partnerships, and growth potential, while assessing the company’s risks.